Lifodrox (Moxifloxacin Hydrochloride)

Moxifloxacin belongs to the fluoroquinolone class and works by inhibiting bacterial DNA gyrase and topoisomerase IV. These enzymes are essential for DNA replication and transcription, so their inhibition leads to bacterial cell death and helps clear the infection.

The dosing regimen for Lifodrox is determined by the prescribing clinician based on the type and severity of the ocular infection. The prescriber will specify the number of drops, frequency, and duration appropriate for each patient.

Safety data for Lifodrox in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Lifodrox, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Lifodrox contains moxifloxacin, which offers a broad spectrum of activity against both Gram‑positive and Gram‑negative ocular pathogens. Compared with older fluoroquinolones such as ciprofloxacin, moxifloxacin often provides higher potency and may require fewer daily administrations, though clinical choice depends on local resistance patterns and physician preference.

Lifodrox should be stored at room temperature, preferably below 25 °C, in its original container. Protect the solution from light and moisture, and keep the cap tightly closed when not in use to maintain sterility.

Lifodrox is applied topically to the eye as directed by the prescriber. Typically, the recommended technique involves washing hands, gently pulling down the lower eyelid, instilling the prescribed number of drops, and avoiding contact between the dropper tip and the eye or any surface.

Serious adverse events, although rare, include corneal ulceration, severe allergic reactions such as anaphylaxis, and sudden vision loss. Patients should seek immediate medical attention if they experience worsening eye pain, increasing redness, loss of vision, or signs of a systemic allergic response.

Lifodrox should not be used by individuals with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any component of the formulation. It is also contraindicated in patients with a history of severe tendon disorders related to fluoroquinolone use.